A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Knight, MD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Republican Clinical Hospital #1
Izhevsk, Russia
- Nizhny Novgorod Clinical Hospital N.A.Semashko
Nizhny Novgorod, Russia
- Novosibirsk State Regional Clinical
Novosibirsk, Russia
- Samara Regional Clinical Hospital
Samara, Russia
- Kharkov Postgraduate Medical Academy Kharkov Regional Clinical
Kharkiv, Ukraine
- Institute of Hematology and Transfusiology of the Uams Department of Blood Diseases
Kiev, Ukraine
- Odessa Regional Clinical Hospital
Odesa, Ukraine
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Apr 2003
- Primary completion
- 25 Nov 2013
- Completion
- 25 Nov 2013
- Last update posted
- 20 Nov 2019
- Registered enrollment
- 330
- Registry id
- NCT00622336
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.